For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Tafamidis meglumine represents a genuine change. These innovative therapies protect the transthyretin protein, halting its destructive build-up and alleviating the impact of the illness. People are now experiencing